Category Archives: Health

What is new in the field of Health. Trending topics, and cutting edge research in the are of Health. Press Releases that give us updates on Health.

New Home Treatment for Pearly Penile Papules (PPP) Removal


For years, the only solution for removing Pearly Penile Papules (PPP) was costly surgeries such as Laser removal. It would cost men suffering from pearly papules from $1,000 to $3,000 to remove them. On top of that, insurance doesn’t cover the cost because it is considered cosmetic surgery.

Indeed, Pearly Penile Papules are a normal anatomic variation and does not cause any health risk. But the look of them can cause anxiety as men with PPP must constantly explain and re-assure their partners about these white dots’ inoffensiveness. Talk about ruining a moment!

PPP KIT is a new HOME treatment for Pearly Papules. It uses an electric Ionizer to vaporize the papules, just like it’s done during laser treatment. The bundle includes everything needed to do it yourself at home, from numbing cream to aftercare healing cream.

Share article on social media or email:

FSAstore.com releases “10 Days, 10 Ways” to spend your remaining 2020 flexible spending account funds


Because of the influence of COVID-19 on access to healthcare services this year, there are hundreds, if not thousands, of dollars left on the line for many American families.

As 2020 comes to a close, the rush of the holiday season will soon turn into a scramble for many flexible spending account (FSA) users who have a December 31 plan year deadline. FSAstore.com, the first online marketplace for exclusively FSA-eligible products and a leading resource for account holder education, released today a list of 10 ways consumers can spend remaining FSA funds in the next 10 days to avoid forfeiting unused dollars.

Why it matters: An FSA is an employer-sponsored, tax-advantaged account that can be used to pay for eligible healthcare expenses. However, money left at the end of each plan year (or after any applicable deadline extension) is forfeited back to the employer. Because of the influence of COVID-19 on access to healthcare services this year, there are hundreds, if not thousands, of dollars left on the line for many American families.

While the FSA spending dash has been a yearly tradition, FSAstore.com believes that spending healthcare dollars should be simple and that forfeiting funds doesn’t have to occur when there are so many options available for account holders to help manage medical conditions and support their long-term health.

With under 2 weeks left to go until the December 31 deadline, FSAstore.com has again published its Deadline Spending Guide to help FSA users understand their options, along with the following 10 ways to spend down funds before time runs out in 10 short days:

1. Diagnostic Products. FSA users looking for a better window into their state of health can use their FSA dollars to purchase at-home COVID test kits, blood pressure monitors, thermometers, pulse oximeters and more.

2. Over-the-Counter (OTC) Medicines. Thanks to the passage of the CARES Act, FSA users can now purchase OTC medicines without a prescription. These include products like pain relievers, antihistamines/decongestants, acne treatments and more that FSA users can save on with their tax-free funds as opposed to paying out-of-pocket. FSA users have even more options this year with the introduction of GoodSense®, FSAstore.com’s private label line of generic OTC medications. With each sale of a GoodSense® product, a portion of the proceeds is donated to the nonprofit charity, Children’s Health Fund.

3. Drug-Free Pain Relief. For people who want drug-free pain relief alternatives, FSA eligible products like acupressure mats, TENS machines, foot rollers, posture pumps and more are just some of the medicine-free pain relief options FSA users can try with their excess health dollars.

4. First Aid. From first aid kits to first aid supplies, FSA users have the opportunity to bolster their medicine cabinets or supplement existing kits they may already have at home, in their car, boat, and everywhere in between.

5. Cold & Allergy. Fall allergies are still a major issue for some, while spring allergy season is just around the corner. In addition to over-the-counter medicines like decongestants and antihistamines, allergy sufferers can also purchase steam inhalers, saline nose wipes, Neti pots and more with their tax-free dollars.

6. Baby & Mom. This is the perfect time for soon-to-be parents to plan ahead with qualifying eligible baby and mom products. An FSA can help new parents get started and save with breastfeeding pumps and supplies, baby movement monitors, nasal aspirators, baby sunscreen and more.

7. Skin & Personal Care. With the expansion of OTC medicines to include products in skin care, FSA users have more opportunities than ever to promote optimal skin health. Keep acne and “maskne” caused by mask usage at bay with eligible acne treatments and light therapy, as well as skin care products used to treat dry skin and eczema.

8. Feminine Care. Feminine care products were made eligible for the first time ever in 2020 thanks to the passage of the CARES Act. FSA users can now expand their yearly budgets to encompass regular purchases like tampons, pads, period underwear, menstrual cups, and more.

9. Sun Care. We’ve all done a lot less traveling in 2020, but those UV rays haven’t gone anywhere. Practice year-round sun care for the whole family with broad spectrum sunscreen for babies, kids and adults, SPF lip balm, moisturizing skin treatments with SPF and more.

10. Eye Care (Glasses, Contacts, Sunglasses). If FSA users need vision correction like glasses and contact lenses, the FSA deadline is the perfect incentive to invest in a new set of prescription frames and lenses, reading glasses, prescription sunglasses or prescription contact lenses. FSAs even cover eyeglass and contact lens care products, like lens cleaning wipes, eyeglass repair kits, as well as contact lens cases and solutions.

The time to spend FSA funds may be running out, but FSA users are better positioned than ever to fully maximize the potential of their tax-free funds to treat medical conditions and promote their long-term health.

To learn more about FSA and deadline spending, visit FSAstore.com.

###

About Health-E Commerce

Health-E Commerce is the parent brand of FSAstore.com, HSAstore.com, and WellDeservedHealth.com, a family of brands serving the 70+ million consumers with tax-free health and wellness accounts. Since 2010, Health-E Commerce’s brand portfolio has led the direct-to-consumer e-commerce market for tax-free health and wellness benefits and helped partners and everyday Americans benefit better through its 100% eligible product selection and easy-to-understand educational resources. Health-E Commerce plays an essential role in consumer advocacy in the tax-free health space through both advocating for eligibility of important new categories within the IRS-approved list of eligible medical expenses and leading a committee of industry experts to promote the important national conversation around product safety and authenticity.

NYC ‘Vein Queen’ Joins Growing NJ and NYC Practice


“As a member of NYC medical royalty, we are honored to have Dr. Rios-Datta join our growing New Jersey and New York City area practice.” — Faisal Siddiqi, M.D., FACC, RPhs, who serves as VSC’s medical director

Vein Specialist Centers announced today that a pioneer for the ground-breaking treatment of spider veins has joined its multi-location practice.

Claudia Rios-Datta, M.D., RPhs will begin practicing today at VSC’s Great Neck, New York as well as Clifton and Paramus, New Jersey offices. Dr. Rios-Datta is a pioneer in cryo-sclerotherapy, which quickly turned spider vein treatments into pain-free, minimally invasive, outpatient procedures in 2000. As a result, the media crowned her the “Vein Queen” during its coverage of the breakthrough medical advancement.

“As a member of NYC medical royalty, we are honored to have Dr. Rios-Datta join our growing New Jersey and New York City area practice,” said Faisal Siddiqi, M.D., FACC, RPhs, who serves as VSC’s medical director, overseeing operations for eight locations throughout New Jersey. “Dr. Rios-Datta brings a wealth of cutting-edge knowledge in vein treatment that will enrich our network of board-certified physicians who continue to deliver a pain-free experience with immediate results.”    

Claudia Rios-Datta, M.D., FAAC, RPhs

Dr. Rios-Datta is board certified in internal medicine. She is a member of the American Board of Venous & Lymphatic Medicine (ABVLM) and a Registered Phlebology Sonographer (RPhs). She received her medical degree from the Universidad Libre De Cali in Colombia and completed her internal medicine residency at Jacobi Medical Center—Albert Einstein School of Medicine.

In 2019, Dr. Rios joined the Hackett Hemwall Patterson Foundation on their vein treatment mission to Honduras, where she used her skills to provide critically needed medical care to the underserved. This experience gave Dr. Rios a deep understanding of the negative effects of venous disease that impacts the everyday life of her patients.

An Innovative, Multi-Specialty Approach

At VSC, a team of physicians has created a better way to treat spider veins and varicose veins. The group of doctors have developed a unique, multi-specialty approach, bringing together board-certified experts in vascular surgery and cardiovascular specialties to deliver a pain-free experience with immediate results.

The practice’s outstanding team of board-certified, Ivy League-trained physicians, which includes vascular surgeons and cardiovascular surgeons, have built a growing practice that truly puts patients’ needs first.

  • VSC’s Ivy League-trained physicians change lives by providing pain-free, minimally invasive treatments, which produce immediate results that allow them to quickly recover.
  • VSC is committed to spending time with every patient, ensuring that they answer all questions. Their attention to every detail has earned high satisfaction ratings in the Greater New York region for the practice.
  • VSC’s spa-like facilities use the latest technology for successful outcomes, ranging from vein treatment to vein therapies.

At VSC, the entire staff takes pride in raising the quality of every patient’s life, so they can quickly resume their on-the-go, busy lifestyle.

To learn more about Vein Specialist Centers, visit the network of physicians.

###

About Vein Specialist Centers

Vein Specialist Centers specialize in minimally invasive therapies that produce pain-free, immediate, life-changing outcomes for active patients who suffer from disorders that include spider veins, varicose veins, restless leg syndrome, deep thrombosis and pelvic venous congestion. Our network of healthcare professionals, which includes our support staff, is patient-focused, ensuring that we are the standard bearer for excellence in patient care. Our board-certified physicians—Ivy League educated and trained—are committed to spending the necessary amount of time with our patients to properly treat them. We have offices throughout New Jersey. For more information, visit our website or call (609) 257-2095.

Share article on social media or email:

nView Expands Digital Behavioral Health Solutions to Support Healthcare Providers


The status quo of mental health screening tools that our public healthcare systems utilize today is failing both our patients and our healthcare providers.

nView Health, a behavioral health solutions company, announced today record revenue growth and geographic expansion in 2020, as more healthcare providers adopt digital assessment tools to address the growing demand for better access to skilled mental health and substance abuse support services.

“This year was an important milestone for the company,” said Jim Szyperski, CEO of nView Health. “We were able to draw upon our years of product experience serving the clinical and academic research sectors to pivot our clinically tried and tested solutions into clinical practice and primary care to help our healthcare professionals meet an overwhelming demand for mental health treatment.”

nView digital behavioral health screeners, diagnostic interviews, and patient outcome monitors are now helping our frontline clinicians more accurately screen their patient populations for mental health and substance abuse disorders. The company’s exclusive core products include the Mini International Neuropsychiatric Interview (M.I.N.I.), which has been cited in thousands of publications; the YBOCS and CYBOCS, which are the leading scales for Obsessive Compulsive Disorders (OCD); and a series of other evidence-based measurement scales that the company continues to develop.

Szyperski continues, “The mental health crisis today is possibly the biggest threat to our generation. The status quo of mental health screening tools that our public healthcare systems utilize today is failing both our patients and our healthcare providers. It is our great privilege to help these professionals better identify, more accurately diagnose and more efficiently monitor patients with behavioral health disorders.”

To support continued growth in the healthcare market, the company also announced today the appointment of two veteran sales leaders:

  • Bob Allen is responsible for the development of strategic partnerships with other software and services companies. Bob has been in professional sales leadership throughout his 20+ year career, working with healthcare technology giants like McKesson, Optum and GE Healthcare.
  • Jason Kosiba is responsible for leading the direct sales efforts at nView. He also brings a rich background of healthcare focused roles in companies like HealthStream, CareerBuilder, and Iron Mountain over the last 20+ years.

“We are delighted to have Bob and Jason onboard to lead our sales directives in 2021 and beyond. Their talent, experience and commitment to our mission is such a welcome addition to our nView team,” added Szyperski.

This past year, nView was successful in installing its solutions at multiple children’s hospitals, large health systems and even independent clinics. In addition to our direct relationships with healthcare providers, nView established global distribution partnerships this year with companies like Checkware in Denmark and Stretch SE in Sweden to help support the global demand for more efficient and effective behavioral healthcare. In North America, nView also successfully created distribution partnerships with patient engagement and electronic healthcare record software vendors to expedite fully integrated solutions into the healthcare system.

About Nview

nView Health offers behavioral health technology that enables healthcare professionals, researchers, and educators to rapidly deliver the right diagnosis, resulting in the right treatment at the right time. Its signature product, the digital M.I.N.I., allows providers to deliver validated diagnostic behavioral health screens, interviews, outcome tracking, and billable services to patients in a simple, easy-to-use platform. To learn more, please visit nview.com or follow nView on LinkedIn or Twitter.

Share article on social media or email:

This Holiday Season, Engage an Aging Life Care Professional® or Corporate Partner to Help with Senior Social Isolation


“ALCA is proud to have over 150 amazing Corporate Partners, each one offering a valuable product or service for older adults and their families,” ALCA CEO Taney Hamill states. “Their adherence to ALCA’s Standards of Practice ensures that people can be confident when engaging with them.”

With the COVID-19 pandemic continuing through the holiday season, Aging Life Care Professionals® and Corporate Partners are continuing to be an essential link between older adults and their families.

Members and Corporate Partners of the Aging Life Care Association® (ALCA) share their commitment to Standards of Practice and a Code of Ethics as they approach the holistic care of an older adult with their services or products.

With many families still far away from their older family member, due to restricted travel warnings, quarantine measures, or practical safety considerations, an Aging Life Care Manager® can help coordinate care to ensure the older adult’s mental or physical health does not suffer.

As Plato said “necessity is the mother of invention” so too have we seen an increase in products and services to help reduce social isolation for older adults during confined time due to the pandemic.

With the increased use of video calls, families and elders are more comfortable using new products such as SoundMind’s voice activated device that uses Amazon’s Alexa to reduce social isolation and keep everyone connected. MyndYou is an app that uses a voice bot to engage with seniors. Using AI that assesses brain activity, it provides care teams with health-related insights. ComforTek’s swiveling chairs or the Personal Living Alert’s Personal Emergency Response systems help older adults when they are living alone. Other services from ALCA partners include meal-delivery services like Moms Meals, therapeutic activity programs like The Hummingbird Project, assisted living resources, travel-assist services like Flying Angels and financial solutions like Care.com HomePay.

Using a Corporate Partner from ALCA is an excellent way for families to be confident in the quality of services or products. Corporate Partners are industry supporters of Aging Life Care who are not solely in the direct practice of Aging Life Care™/care management as defined by ALCA, but have an interest in the field, including elder law attorneys, physicians, educators, researchers, home health agencies, nursing homes, assisted living facilities, manufacturers or distributors of durable medical equipment or other products or services related to the care of elders.

About the Aging Life Care Association®

Aging Life Care Association® was formed in 1985 to advance dignified, coordinated care for older adults in the United States. Founded by and handful of women entrepreneurs in the social work and nursing fields, the Association has grown to over 2000 members nationwide, who have cared for about two million older adults over its 35-year history. Members have extensive training and experience working with older adults, people with disabilities, and families who need assistance with caregiving issues. Members must meet stringent education, experience, and certification requirements. Members may be trained in any of number of fields related to long-term care, including nursing, social work, and other allied health professions with a specialized focus on issues related to aging. All members are required to adhere to a strict Code of Ethics and Standards of Practice. Aging Life Care™ and the role of care providers have captured a national spotlight with the onset of the global pandemic, and as generations of Baby Boomers age in the United States and abroad.

For more information or to access the directory of Aging Life Care Corporate Partners, please visit https://www.aginglifecare.org/ALCA/Find_a_Corporate_Partner/ALCA/Corporate_Partners_and_Sponsors/Find_Corporate_Partners.aspx?hkey=c82dfc0d-d988-4fbb-9c23-da3289f06221

Share article on social media or email:

True Terpenes Expands Leading Safety Program to Set Industry Standards for Testing and Compliance


“As industry leaders, we believe that we are in a unique position to help regulators use proper test methodology and sound science in their decision-making processes,” said True Terpenes CEO Chris Campagna.

True Terpenes, the leading global platform for terpenes innovation, research, and development, today announced the expansion of its Testing and Safety Program. The company hired Shawna Vreeke, Ph.D. as its first Senior R&D Chemist to spearhead the Program in early August 2020, building on its long-standing commitment to public safety, including the first company to feature GMP/ISO certifications, and the most stringent safety testing program in the terpene industry with the lowest allowable levels of contaminants.

In a role not typically found at companies servicing the cannabis industry, Dr. Vreeke is responsible for investigating each compound used in True Terpenes products and identifying potential health risks associated with its common end uses. While True Terpenes is a B2B supplier and does not manufacture consumer goods, True Terpenes expects to build the most robust database of safety information in the terpene industry, and support policy-makers with pragmatic and specific guidelines to advance public safety, establish standards for testing in real-world scenarios, and provide consistent regulatory frameworks informed by science.

The company is addressing evident gaps in the science and research surrounding the safety of cannabis products and using these findings to inspire finished goods that optimize these discoveries. Dr. Vreeke’s complete safety analysis of True Terpenes’ products is underway, and initial results will be available in early 2021. The initial analysis includes a comprehensive review of available literature, thermal degradation, and exposure limits to create guidelines that will be shared with regulators to support future safety testing programs and regulations. True Terpenes remains committed to taking meaningful steps every day toward an even more full understanding of the plant and its interactions with ingredients and hardware used in various manufactured products and delivery systems.

“We have seen some questionable data used to make conclusions and often the results are incomplete and not representative of real-world use,” said Shawna Vreeke, Senior R&D Chemist at True Terpenes. “In my new position, I will be setting the highest standard for testing and safety with True Terpenes, and publishing research that expands public knowledge of potential health risks that is critical for consumers, manufacturers, and regulators as the cannabis industry expands.” With a Ph.D. in chemistry, Vreeke brings experience in biopharmaceuticals and quality control. Dr. Vreeke earned her doctorate from Portland State University, where she received the Paul Emmet Award for Excellence in Research for her studies on electronic cigarettes’ toxin formations under Dr. Robert Strongin.

“With the continued advancement of the cannabis industry, we anticipate regulatory refinement on the state and federal level, as we’ve seen in recent months,” said True Terpenes CEO Chris Campagna. “As industry leaders, we believe that we are in a unique position to help regulators use proper test methodology and sound science in their decision-making processes. Our SAB, R&D, and Quality Assurance team has two PhDs, five Chemists with Master’s Degrees, and a Medical Doctor. We will continue to encourage regulators to leverage our internal resources and work together to make a stronger and safer industry.”

Dr. Vreeke will work in tandem with Andre Martinez, Director of Technology at True Terpenes, to ensure all findings are reflected throughout the manufacturing process, as well as identifying and implementing innovative avenues of research. As an analytical chemist, Martinez has spent the last fifteen years investigating and developing methodologies to purify natural compounds that impact human health and wellness. In his role with True Terpenes, he has sought to use the applications of science and technology to bridge the gap between product development and market execution, and established new standards and methods to expand research capabilities throughout the industry.

On a related note, following the recent regulatory actions taken by the Oregon Liquor Control Commission (OLCC) with respect to cannabis vape products, which banned certain purported adulterants and modified labeling requirements, True Terpenes applauded the regulatory commission on its commitment to creating a safer industry. In response, True Terpenes swiftly moved to broaden its already comprehensive safety program to further its investment in guiding the cannabis industry in safe and reliable practices.

Upon notification of the OLCC investigation, True Terpenes immediately and voluntarily contacted all affected customers and began an unprecedented partnership with the OLCC to support the regulatory agency. The company provided its research related to the additives and guidance on available data to support the OLCC’s investigation. True Terpenes also offered clarifications regarding the validity of the agency’s conclusions and presented missing data based upon real-world use scenarios.

The OLCC singularly praised True Terpenes for being helpful in its investigation and highlighting the many recognized unknowns about its analysis. “They [True Terpenes] have offered their help and assistance, and certainly without them, we could not have, as speedily, identified where their third party mix got into our market,” said OLCC Executive Director Steve Marks.

“We see this action as the beginning of a new era of very productive cooperation between True Terpenes, policy-makers, and other key stakeholders highly invested in making the Oregon cannabis market a safer place,” said True Terpenes CEO Chris Campagna. “We see our partnership with the OLCC as the beginning of a unique and necessary relationship between True Terpenes and regulators across Oregon and throughout the country. As a relatively new and emerging marketplace, it’s vital that regulators and industry participants work together to create safer products and better-educated consumers. With an increased focus on research and data, the industry will strengthen, and so will consumer confidence.

Earlier this year, True Terpenes launched a Scientific Advisory Board to research the medical potential of terpenes and the entourage effect, where the benefits of medical cannabis can be enhanced when combined with terpenes. The Board is composed of several leading researchers, including Dr. Randall Murphy, former Chief Science Officer and Co-Founder of Metagreen. Dr. Murphy has spent a career in small molecule development for advanced medical applications in the biotechnology, pharmaceutical, academic, and public sectors. The Board is led by pioneering cannabis researcher, Dr. Ethan Russo, a board-certified neurologist and trailblazing researcher of the entourage effect, minor cannabinoids, and terpene science.

About True Terpenes

True Terpenes is the industry-leading producer of terpene and terpenoid blends, manufactured in a state of the art GMP/ISO/FSSC facility. Using ultra-refined botanical terpenes and other phytocompounds, the unique blends are used for beverage, cannabis, cosmetic, food, industrial, and pharmaceutical products. The company uses advanced scientific analysis and specialized formulations to provide a scalable, safe, and legal solution for companies in various industries looking to leverage cannabis flavors and effects.

About Shawna Vreeke, Ph.D., Senior Research and Development Chemist, True Terpenes

Dr. Shawna Vreeke earned her PhD in Chemistry in 2019 for her investigation into electronic cigarettes’ toxin formation. She identified different flavor additives and devices that led to increased toxic formation within the inhaled aerosol. Shawna was awarded the Paul Emmet award for her excellence in research from Portland State University. Outside of academia, she has worked at Baxter Bioscience, a start-up biotechnology company, and her current position as a chemist at True Terpenes. Shawna is passionate about the therapeutic properties of natural products and understands the importance of developing science based guidelines to protect consumer safety.

About Andres Martinez, M.S., Director of Technology, True Terpenes

An analytical chemist by training, Andres has spent the last fifteen years of his career investigating and developing methodologies to purify natural compounds that impact human health and wellness. Andres began his work in the cannabis industry over ten years ago by investigating the entourage effect synergies between cannabis terpenes and beer. Over the last five years, Andres has expanded his focus to include the application of science and technology to bridge the gap between product development and market execution. Specifically, he has established standards and new methodologies to expand capabilities in the realm of chromatography, remediation of pesticides and isolation of minor components in complex plant matrices with the goals of maximizing longevity and increasing quality of life.

Prior, Andres amassed well over a decade of experience in both the public and private sectors, working on problems such as: drinking water remediation, heavy metals in fish, pesticides in wine, groundwater management, pesticides in foods, and proxy methods driving abrupt climate change. Andres holds a B.S and an M.S. degrees from the University of Southern California, is an avid homebrewer, and is an active participant in local youth science programs.

Disclaimer

The foregoing statement contains “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: “anticipate,” “intend,” “plan,” “goal,” “seek,” “believe,” “project,” “estimate,” “expect,” “strategy,” “future,” “likely,” “may,” “should,” “will” and similar references to future periods. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only upon the Company’s current beliefs, expectations and assumptions regarding the future of its business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of the Company’s control.

Any forward-looking statements included in this document are made as of the date of this document and the Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise. Although the Company’s management believes that the expectations represented in such forward-looking statements are reasonable, there can be no assurance that such expectations will prove to be correct.

This lab is helping fight the STI testing shortage caused by COVID-19


MicroGenDX Logo

MicroGenDX Logo

MicroGenDX has over 11 years’ experience designing, and validating laboratory developed tests and mitigating risk in supply chains so that we are able to run the test you need when you need it.

In an era when shortages abound, having options is invaluable. Worldwide, labs are facing a scarcity of supplies, as those needed to test for diseases such as sexually transmitted infections (STIs) must be diverted to Covid-19 testing. Enter MicroGenDX, a company specializing in qPCR + Next Generation Sequencing (NGS) microbial molecular diagnostics…a company that designs and set up its own tests and multiplex panels in-house

Indeed, the lack of supplies for STI testing is so severe that in September, the Centers for Disease Control and Prevention advised physicians that if they encounter shortages, then it may be necessary to ration tests for chlamydia and gonorrhea, prioritizing those at higher risk.

In a typical testing situation, lab personnel load a pre-made cartridge with reagents into PCR machines—which typically uses reagents from the same manufacturer. So, when thousands of people are awaiting tests for STIs, pneumonia, and other potentially life-threatening infections, these results are delayed because resources have been shifted to Covid-19 testing. Thus, in the case of STIs, many go undiagnosed, or are clinically treated without testing and in more concerned cases, leading to asymptomatic infected individuals continuing to unknowingly spread the disease.

“MicroGenDX is not as often affected by supply chain issues experienced by other test providers as we design our tests in-house,” says Nick Sanford, Ph.D., Section Director, MicroGenDX, “which means that if there is a shortage of a particular component of the test, we can usually find a replacement from another supplier. Using kits means reliance on every piece of that kit from that kit’s manufacturing supply chain. We have designed our own test so that we have the option of substituting when necessary. MicroGenDX has over 11 years’ experience designing, and validating laboratory developed tests and mitigating risk in supply chains so that we are able to run the test you need when you need it.”

The company’s in-house test, known as a LDT (Lab Developed Test), is regulated and validated by the College of American Pathology (CAP) and CLIA (Clinical Laboratory Improvement Amendments) Act. MicroGenDX designs, validates, and clinically implements its own LDT under its CAP license which means they can use different reagents or suppliers. Thus, MicroGenDX has no shortage of supplies because they are not competing with other labs for supplies.

MicroGenDX can perform a basic STI Panel, a urine test that screens for Chlamydia trachomatis and Neisseria gonorrhoeae (CT/NG). The company also performs a an additional STI (called “Full STI” by MicroGenDX) molecular panel (urine) is able to identify Chlamydia trachomatis, Neisseria gonorrhoeae, Trichomonas vaginalis, and Mycoplasma genitalium (CT/NG/TV/MG). Both can be ordered directly from the company’s website by a prescriber provider or via MicroGenDX’s telehealth partner, Medcall. MicroGenDX will also add STI testing on top of its Urine, Vaginal, and Prostate Testing services at no additional cost. Results, for the STI tests alone, are returned within 24-48 hours from the time they are received at the laboratory.

The company also accepts the following sample types from healthcare institutions: urine, semen, semen swab, rectal swab, urogenital swab, and vaginal swabs.

Additional information on MicroGenDX’s STI Products is at https://microgendx.com/sti-testing/

About MicroGenDX

MicroGenDX is a College of American Pathologists (CAP) accredited and Clinical Laboratory Improvements Amendments (CLIA) licensed clinical laboratory with more than 12 years of experience in diagnosing molecular-based, laboratory-developed tests. MicroGenDX operates a high-complexity diagnostic laboratory that uses Polymerase Chain Reaction (PCR) and Next Generation DNA Sequencing Technology (“NGS Technology”) – rather than the traditional approach of growing cultures – to determine the presence of, and identify by their genetic markers, specific micro-organisms that are the cause of infections.

MicroGenDX’s technology and mission are improving and saving the lives of patients with serious and often chronic infections and diseases by using the latest science and the most precise diagnostic tool available to identify the cause of infection so that the most effective medicine can be prescribed to treat that infection. Thousands of patients with chronic and often life-threatening infections have benefited from MicroGenDX’s work.

Share article on social media or email:

Google, Hopkins, FDA, Pall and Boston Scientific alumni release Canopy, a transparent reusable respirator to solve N95 crisis; can produce millions of units per year


Dr. Narissa Joyner, Emergency Medicine physician wearing Canopy

Dr. Narissa Joyner, Emergency Medicine physician wearing Canopy

“Given the significant limitations, drawbacks and shortages of existing PPE, we are eager for our staff to begin testing Canopy in the clinical setting. It cannot come soon enough.” said Dr. Yves Duroseau MD MPH, Chief of Emergency Medicine at Lenox Hill Hospital, a Northwell Health Hospital.”

Grove Biomedical, a medical device startup founded in April 2020 announced today the launch of Canopy, a modular ecosystem of transparent, reusable respirators developed in collaboration with clinicians and hospital administrators to solve the most common issues with the disposable N95’s half-century-old design.

Canopy’s patent-pending solution was inspired by feedback from dozens of Emergency Medicine professionals to ameliorate their key complaints with current solutions, which include: discomfort, poor breathability, and challenges communicating with colleagues and patients. Beyond the value to frontline workers and patients, Canopy can save hospitals thousands of dollars per employee per year while reducing wasteful single-use PPE and supply chain risk.

Compared to a disposable N95, Canopy’s engineers were able to fit nearly three times more filter media into the device’s transparent Core. The achievement unlocked a universe of materials that avoids globally-scarce meltblown media, a key cause of worldwide N95 shortages. In company-sponsored testing at SGS Labs, Fiatec GmbH and Nanosafe Inc., Canopy achieved up to 99.8% filtration of 0.3 micron-sized particles under certain test conditions. The company has partnered with the world’s largest sterile air filter OEM to mass-produce the proprietary Filter Core. It expects to deliver initial orders in early Q1 and has capacity to produce millions of units per year, made in the USA with several globally sourced components.

“Given the significant limitations, drawbacks and shortages of existing PPE, we are eager for our staff to begin testing Canopy in the clinical setting. It cannot come soon enough,” said Dr. Yves Duroseau MD MPH, Chief of Emergency Medicine at Lenox Hill Hospital, part of Northwell Health, New York’s largest health system. Canopy is collaborating with both Northwell and Emory University on an evaluation comparing Canopy to disposable N95s, and with researchers at Emory University to evaluate Canopy’s features and benefits compared to disposable N95s.

Joe Rosenberg, a past leader in Google’s Emerging Business Development group, founded the company and recruited Qing Xiang “QX” Yee as Chief Engineer. QX holds a graduate degree from Johns Hopkins’ Center for Bioengineering Innovation and Design. Rosenberg tapped Dr. Tom Gsell, PhD, the long-tenured R&D executive at Pall Corporation, a worldwide leader in medical filtration, to help perfect the filter design.

Canopy is a fully modular line of interchangeable straps and filters to suit a variety of use-cases. Canopy, the eponymous base-model, and Canopy Pro, which is pending NIOSH certification, are available for pre-order on the company’s website onecanopy.com. Deliveries are expected in Q1 2021.

Canopy also obtained B Corporation Pending status, the highest B Lab certification for companies less than a year old. “Canopy’s mission is to protect the world’s well-being. We are pleased that we can directly align financial success with positive social and environmental impact” said Rosenberg.

The founders recently began raising external capital on the Republic.co platform, allowing individuals to invest as little as $100 in the company. “We want those who believe in our mission to be able to share in our success,” said Rosenberg.

About Canopy

Led by Google, Johns Hopkins, DaVita, Boston Scientific & Pall alumni, Canopy is dedicated to protecting the world’s well-being by creating sustainable products that increase comfort, safety, and performance. The medical device startup’s flagship product, Canopy, is a supremely comfortable, transparent, and reusable respirator, designed to address the top shortcomings of current N95 disposable respirators.

Email: info@onecanopy.com

Instagram: @one.canopy

Twitter: one_canopy

Facebook: meetcanopy

LinkedIn: linkedin.com/company/onecanopy

Republic: republic.co/canopy

Media Kit: https://docsend.com/view/hs8amfwpdudhdpck

Share article on social media or email:



After Two Years of Rehabilitation, Abused, Starved Dog Finds a Home for the Holidays


Marty was abused, starved and kept in a wire cage with no fresh air. He finally found his forever home this week, after two years of rehabilitation.

“Marty had every reason in the world to be aggressive toward humans, but he never was. He showed us nothing but love and trust. This is why we fight every day for animals like him. I can’t think of a better holiday gift than finding a home for such a deserving dog.”

When he was rescued in 2019, Marty the dog was emaciated, covered in painful sores, and barely clinging to life. This week, after nearly two years of rehabilitation at Pasado’s Safe Haven, Marty was able to go home with his forever family for the holidays.

“Marty is doing terrific,” said Steve Klein, Marty’s new dad. “He is melding right into our quiet, rural life.”

It is a far cry from where Marty started in life just a few short years ago. Marty – who resembles the “KitBull” dog from the award-winning Disney short — was abused, neglected, and starved. He was kept in a wire cage in a garage with no fresh air and never given consistent access to the outside. Injuries were not treated, and he never learned common social skills. When his owners abandoned their rental house, they left Marty and two other dogs locked inside the cages without food or water.

“Marty was incredibly lucky that the landlord found the dogs and called police to help,” said Laura Henderson, executive director of Pasado’s Safe Haven, the Pacific Northwest’s leading animal sanctuary and rescue organization. Regional Animal Services of King County acted quickly and brought Marty and the two other dogs to a local shelter. But while the other two dogs found homes, Marty began to emotionally shut down. He was suffering from significant mental trauma – a common occurrence for animals that have been abused and neglected. The shelter called Pasado’s Safe Haven for help.

“Marty is the kind of dog that many shelters just can’t take on, because getting them to the point where they are adoptable takes a very long time – and sometimes never happens,” Henderson said. “Our mission is to rescue and rehabilitate animals that have nowhere else to go. Our caretakers are uniquely qualified to help animals who need little extra time to heal, both physically and emotionally.”

Marty was extremely afraid of new people (especially men) and suffered from severe separation anxiety. Bryana Walters, behaviorist at Pasado’s Safe Haven, designed a unique care plan to address Marty’s specific needs.

“With Marty, the key was convincing him that life could and would be different,” said Walters. “We needed to retrain his brain to understand that a previously negative thing could be a positive thing. We rewarded Marty every time he simply looked at a stranger and stayed calm and relaxed. Eventually, he was able to meet new people with no issues.”

Marty also started medication for his anxiety and was rewarded each time he sat calmly in a room by himself as caretakers went in and out of the door. Lastly, Walters taught Marty how to “self-soothe” – providing him with a safe place to go when he felt uneasy. The key, Walters said, was finding methods that not only worked for Marty but also could easily be taught to his new family.

“Bryana taught us the training exercises, which we’ve incorporated into our daily life with Marty,” said Klein, who got the idea to rescue a dog from a retirement magazine article about how to give back this holiday season. “(My wife) and I feel he is becoming more and more trusting every day.”

Henderson added: “Marty had every reason in the world to be aggressive toward humans, but he never was. He showed us nothing but love and trust. This is why we fight every day for animals like him. I can’t think of a better holiday gift than finding a home for such a deserving dog.”

Pasado’s Safe Haven, the Pacific Northwest’s leading animal sanctuary and rescue organization, is leading the fight against animal cruelty and works to create a world where every animal is protected. Our uniquely comprehensive approach to ending animal cruelty holds abusers accountable, provides sanctuary and rehabilitation to animals who have suffered from abuse/neglect, advocates for better laws to keep animals safe, and works to inspire people to grow their circle of compassion to include all animals. Follow us on Twitter, Facebook or Instagram for daily updates on rescues as well as animals in our care or visit our website at http://www.pasadosafehaven.org.

Share article on social media or email:

Easton Industrial Air Launches Steril-Aire Ultraviolet-C Air Purification Systems to Help Industries Get Back To Work


We hope these systems are widely adopted to prevent the spread of pathogens, not just in the energy sector, but any indoor workplace.

Since 2002 Easton Air has been designing and distributing HVAC systems for some of the energy sector’s largest projects.

“In all our years of business we have never seen a disruption to the industry like we’re seeing now,” says Bill Easton, founder and president of Easton Air. “We can see employers and employees are both nervous right now about health and safety. We’ve been looking for a solution that can help our clients keep safe while continuing work and have been so impressed with the results of the Steril-Aire UVC systems.”

The Steril-Aire UVC technology has been third party tested and FDA approved for use in small businesses all the way up to industrial work sites. The Steril-Aire system can be added to existing HVAC systems, as well as utilized in room with portable and handheld units, to eliminate up to 99% of airborne contaminants, while reducing ongoing maintenance costs on the existing HVAC hardware.

Benefits of installing a Steril-Aire UVC system include

  • Reduce airborne contaminants by up to 99%
  • Fits into an existing HVAC system
  • Seven times more powerful than the nearest competitor
  • Third party researched and proven to be effective in the extermination of aerosol transmitted illnesses


“Work stoppages have been an ongoing issue over the past year. We’re excited to have found a solution that will help our industry, and province, get back to work while staying safe,” says Easton. “Health and safety have to be our number one priority and we are excited to be offering Steril-Aire UVC. We hope these systems are widely adopted to prevent the spread of pathogens, not just in the energy sector, but any indoor workplace.”

Share article on social media or email: